All In Biotech

Drug Trial Radar · NCT01066962

Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects

An Open-label Randomised Two-year Trial Comparing Two First-line Regimens in HIV-infected Antiretroviral naïve Subjects: Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir (ANRS 143/NEAT 001)

Last checked: Nov 19, 2026Latest source record: Nov 6, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 800 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

800

Actual

Start

Aug 2010

Primary completion

Oct 2013

Study completion Oct 2013

Sponsor

Lead sponsor
ANRS, Emerging Infectious DiseasesGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
NEAT - European AIDS Treatment Network
First posted
Feb 10, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The triple therapy darunavir/r + tenofovir/emtricitabine is likely to become a relevant first-line treatment option in the years to come. The dual combination of boosted darunavir + raltegravir is an innovative treatment option that combines two potent new antiretroviral drugs, one of which belongs to a new drug class (integrase inhibitor). The expected efficacy profile of this combination is promising. Moreover, this combination might have a better tolerance profile and has the advantage of sparing the NRTI class. In the context of tenofovir/emtricitabine currently being a reference backbone in first-line antiretroviral regimens, we hypothesise that, in combination with darunavir/r, raltegravir may be an alternative option if its efficacy is non-inferior to tenofovir/emtricitabine.

Conditions

  • HIV Infections

Interventions

  • darunavir/ritonavir QD + raltegravir BIDDrug

    darunavir 800 mg, i.e. 2 tablets of 400 mg once daily (QD) ritonavir 100 mg, 1 tablet once daily (QD) raltegravir 400 mg, 1 tablet twice daily (BID)

  • darunavir/r QD + tenofovir/emtricitabine QD (fixed dose combination)Drug

    darunavir 800 mg, i.e. 2 tablets of 400 mg once daily (QD) ritonavir 100 mg, 1 tablet once daily (QD) tenofovir/emtricitabine 245/200 mg, fixed dose combination, 1 tablet once daily (QD)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to virologic or clinical failure, as the first occurrence of one of six protocol-defined componentsTime frame: minimum 2 years

Locations

77 sites in 15 countries. Site status is shown where the registry gives one.

  • Allgemeines Krankenhaus der Stadt Wien

    Vienna, Austria

  • Otto Wagner Spital mit Pflegezentrum

    Vienna, Austria

  • ITZ Antwerpen

    Antwerp, Belgium

  • CHU Saint Pierre

    Brussels, Belgium

  • UZ Gent

    Ghent, Belgium

  • Rigshospitalet

    Copenhagen, Denmark

  • Hvidovre Hospital

    Hvidovre, Denmark

  • Hôpital Pellegrin

    Bordeaux, France

  • Hôpital Saint André

    Bordeaux, France

  • Hôpital Henri Mondor

    Créteil, France

  • Hôpital du Bocage

    Dijon, France

  • Hôpital Pierre Zobda-Quitman

    Fort de France, France

  • CHD de la Roche sur Yon

    La Roche-sur-Yon, France

  • Hôpital Bicêtre

    Le Kremlin-Bicêtre, France

  • Hôpital Gui de Chauliac

    Montpellier, France

  • Hôpital de l'Hôtel Dieu

    Nantes, France

  • Hôpital Bichat

    Paris, France

  • Hôpital Européen Georges Pompidou (HEGP)

    Paris, France

  • Hôpital La Pitié Salpétrière

    Paris, France

  • Hôpital Saint Antoine

    Paris, France

  • Hôpital Saint Louis

    Paris, France

  • Hôpital Pontchaillou

    Rennes, France

  • Hôpital Foch

    Suresnes, France

  • Hôpital Purpan

    Toulouse, France

  • Hôpital Gustave Dron

    Tourcoing, France

  • Gemeinschaftspraxis Jessen-Jessen-Stein

    Berlin, Germany

  • Med. Universitätsklinik I

    Bonn, Germany

  • Universitätsklinik Köln

    Cologne, Germany

  • Universitätsklinikum Essen

    Essen, Germany

  • Klinikum der Johann Wolfgang Goethe Universität

    Frankfurt, Germany

  • Asklepios-Klinik St. Georg

    Hamburg, Germany

  • ICH study centre

    Hamburg, Germany

  • Medizinische Hochschule Hannover

    Hanover, Germany

  • Attikon University Hospital

    Athens, Greece

  • Evaggelismos General Hospital

    Athens, Greece

  • Laikon General Hospital

    Athens, Greece

  • Saint Laszlo Hospital

    Budapest, Hungary

  • Mater Misericordiae

    Dublin, Ireland

  • St James's Hospital

    Dublin, Ireland

  • University of Brescia

    Brescia, Italy

Showing 40 of 77 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.